Royal Peptides LLC — FDA Warning Letter, 2026-08-24: Unapproved New Drugs/Misbranded
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs/Misbranded
TL;DR
At a glance: The FDA Center for Drug Evaluation and Research (CDER) issued a warning letter to Royal Peptides LLC (managers Rocco Abate and Michael Fraunfelter, Boynton Beach, FL) on August 24, 2026 (Reference 734884) citing unapproved new drug violations under sections 301(d) and 505(a) of the FD&C Act for seven peptides: Tirzepatide, Semaglutide, Retatrutide, SS-31 (Elamipretide), PT-141, Tesamorelin, and BIMORELIN. Website content reviewed in July 2026 described these products with claims of effects on glucose regulation, insulin sensitivity, weight loss, metabolism, and body composition, establishing their intended use as drugs without FDA approval. The letter states injectable drug products pose particular public health risk due to direct delivery into the body, bypassing natural defenses, and warns that failure to address violations may result in seizure, injunction, or other regulatory action.
Argus analysis
# FDA Warning Letter Analysis: Royal Peptides LLC
**Company and Violations**
Royal Peptides LLC, a Florida-based firm operated by Rocco Abate and Michael Fraunfelter, received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) on August 24, 2026. The FDA conducted a website review in July 2026 and identified seven products marketed as unapproved new drugs: Tirzepatide, Semaglutide, Retatrutide, SS-31 (Elamipretide), PT-141, Tesamorelin, and BIMORELIN. The FDA noted particular public health concern because these are injectable products that bypass the body's natural defenses, creating risk of serious harm including infection and toxicity.
**Regulatory Citations**
The violations center on sections 505(a) and 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(a) and 321(g)(1)), along with section 301(d) (21 U.S.C. 331(d)). These provisions require FDA approval before marketing drugs intended to diagnose, cure, treat, or prevent disease, or affect body structure or function. Royal Peptides' website contained clinical efficacy claims—such as "up to 22.5% body weight reduction" for Tirzepatide and "24.2% body weight reduction" for Retatrutide—demonstrating intended drug use. The company marketed these products without approved New Drug Applications (NDAs), making them illegal to distribute across state lines.
**Next Steps and Industry Observations**
Royal Peptides has until the response deadline (the letter was truncated but typically allows 15 business days) to submit written corrective actions to FDAAdvisory@fda.hhs.gov. Compliance peers should monitor whether the company removes products, revises labeling claims, or contests findings. The FDA warned that failure to comply may trigger seizure, injunction, or criminal referral. Similar peptide distributors marketing research-only products with clinical language face comparable enforcement risk.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Royal Peptides LLC MARCS-CMS 734884 — August 24, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: Recipient Name Rocco Abate and Michael Fraunfelter Recipient Title Managers Royal Peptides LLC 2310 SE 2nd St. Ste 7 Boynton Beach , FL 33435 United States admin@royal-peptides.com info@royal-peptides.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States August 24, 2026 WARNING LETTER Reference Number: 734884 To Rocco Abate and Michael Fraunfelter: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions. FDA Review Violations were identified and documented during a review of your website royal-peptides.com in July 2026. Based on our review, “Tirzepatide,” “Semaglutide,” “Retatrutide,” “SS-31 (Elamipretide),” “PT-141,” “Tesamorelin,” and “BIMORELIN” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations. Unapproved New Drug Violations Based on a review of your website, “Tirzepatide,” “Semaglutide,” “Retatrutide,” “SS-31 (Elamipretide),” “PT-141,” “Tesamorelin,” and “BIMORELIN” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure,…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the regulatory background for a Unapproved drug warning letter?
- Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Royal Peptides LLC had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Royal Peptides LLC as of 2026-09-01. Argus ingests new FDA enforcement records daily.
- What FDA violations was Royal Peptides LLC cited for?
- The FDA Warning Letter to Royal Peptides LLC (issuing office: Center for Drug Evaluation and Research (CDER)) cites: Unapproved New Drugs/Misbranded. Classification: Unapproved drug.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Royal Peptides LLC — FDA Warning Letter, 2026-08-24: Unapproved New Drugs/Misbranded. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-royal-peptides-llc-2026-08-24-unapproved-drug
"Royal Peptides LLC — FDA Warning Letter, 2026-08-24: Unapproved New Drugs/Misbranded." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-royal-peptides-llc-2026-08-24-unapproved-drug.
Argus HQ Research. "Royal Peptides LLC — FDA Warning Letter, 2026-08-24: Unapproved New Drugs/Misbranded." Digital Empire Holdings LLC. Accessed September 2, 2026. https://argushq.ai/fda/warning-letter/fda-wl-royal-peptides-llc-2026-08-24-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_royal_peptides_llc_2026_08_24_unapproved_drug_2026,
title = {Royal Peptides LLC — FDA Warning Letter, 2026-08-24: Unapproved New Drugs/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-royal-peptides-llc-2026-08-24-unapproved-drug},
note = {Accessed: September 2, 2026}
}